Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel plus vandetanib versus docetaxel plus placebo in advanced NSCLC after failure of first-line therapy
2005-004749-32Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Docetaxel plus vandetanib with Docetaxel plus placebo (2 arms). Primary endpoint: Progression-free survival. Started Feb 2006; status: completed.
02
Drugs
vandetanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2005-004749-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004749-32.